Search

Search Constraints

You searched for: Author/Creator Schulze-Koops, Hendrik

Search Results

1. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Issue 1 (7th October 2021)

2. 272 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial. (12th April 2019)

3. 351. EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL. (29th March 2019)

5. Activation of pregnane X receptor inhibits experimental dermal fibrosis. Issue 4 (4th January 2013)

7. Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Issue 1 (12th October 2020)

9. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Issue 9 (28th May 2021)

10. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Issue 8 (13th May 2020)